Minority Views
[To accompany H.R. 2666]
The Committee on Energy and Commerce, to whom was referred
the bill (H.R. 2666) to amend title XIX of the Social Security
Act to codify value-based purchasing arrangements under the
Medicaid program and reforms related to price reporting under
such arrangements, and for other purposes, having considered
the same, reports favorably thereon with an amendment and
recommends that the bill as amended do pass.
CONTENTS
Purpose and Summary.............................................. 4
Background and Need for Legislation.............................. 4
Committee Action................................................. 4
Committee Votes.................................................. 5
Oversight Findings and Recommendations........................... 7
New Budget Authority, Entitlement Authority, and Tax Expenditures 7
Congressional Budget Office Estimate............................. 7
Federal Mandates Statement....................................... 7
Statement of General Performance Goals and Objectives............ 7
Duplication of Federal Programs.................................. 7
Related Committee and Subcommittee Hearings...................... 7
Committee Cost Estimate.......................................... 8
Earmark, Limited Tax Benefits, and Limited Tariff Benefits....... 8
Advisory Committee Statement..................................... 8
Applicability to Legislative Branch.............................. 8
Section-by-Section Analysis of the Legislation................... 8
Changes in Existing Law Made by the Bill, as Reported............ 9
Minority Views................................................... 68
The amendment is as follows:
Strike all after the enacting clause and insert the
following:
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Medicaid VBPs for Patients Act'' or
the ``MVP Act''.
SEC. 2. CODIFYING VALUE-BASED PURCHASING ARRANGEMENTS UNDER MEDICAID
AND REFORMS RELATED TO PRICE REPORTING UNDER SUCH
ARRANGEMENTS.
(a) Codifying Multiple Best Price Points.--
(1) In general.--Section 1927(c)(1)(C)(ii) of the Social
Security Act (42 U.S.C. 1396r-8(c)(1)(C)(ii)) is amended--
(A) in subclause (IV), by striking ``and'' at the
end;
(B) in subclause (V), by striking the period and
inserting ``; and''; and
(C) by adding at the end the following new subclause:
``(VI) may include multiple best
price points for a single dosage form
and strength of a drug of a
manufacturer subject to a value-based
purchasing arrangement (as defined in
subsection (k)(12)), but only if such
manufacturer offers such arrangement to
all States.''.
(2) Rule of construction.--Nothing in the amendments made by
this subsection may be construed to prohibit a manufacturer
from treating a value-based purchasing arrangement as a bundled
sale.
(b) Definition of Average Manufacturer Price.--
(1) In general.--Section 1927(k)(1) of the Social Security
Act (42 U.S.C. 1396r-8(k)(1)) is amended--
(A) in subparagraph (B)(i)--
(i) in subclause (VII), by striking at the
end ``and'';
(ii) in subclause (VIII), by striking the
period at the end and inserting ``; and''; and
(iii) by adding at the end the following new
subclause:
``(IX) with respect to such covered
outpatient drug that is sold under a
value-based purchasing arrangement (as
defined in paragraph (12)) during the
rebate period, including such drug that
is an inhalation, infusion, instilled,
implanted, or injectable drug that is
not generally dispensed through a
retail community pharmacy--
``(aa) a refund, rebate,
reimbursement, or free goods
from the manufacturer or third
party on behalf of the
manufacturer; or
``(bb) the withholding or
reduction of a payment to the
manufacturer or third party on
behalf of the manufacturer;
that is triggered by a patient who
fails to achieve outcomes or measures
defined under the terms of such value-
based purchasing arrangement during the
period for which such arrangement is
effective.''; and
(B) by adding at the end the following new
subparagraph:
``(D) Special rule for certain value-based purchasing
arrangements.--For purposes of subparagraph (A), in
determining the average price paid to the manufacturer
for a covered outpatient drug that is sold under a
value-based purchasing arrangement (as defined in
paragraph (12)) that provides that payment for such
drug is made in installments over the course of such
agreement, such price shall be determined as if the
aggregate price per the terms of the agreement was paid
in full in the first installment during the rebate
period.''.
(2) Rulemaking.--Not later than 180 days after the date of
the enactment of this Act, the Secretary of Health and Human
Services shall implement the amendments made by this subsection
through rulemaking.
(c) Definition of Value-based Purchasing Arrangement.--Section
1927(k) of the Social Security Act (42 U.S.C. 1396r-8(k)) shall be
amended by adding at the end the following paragraph:
``(12) Value-based purchasing arrangement.--The term `value-
based purchasing arrangement' has the meaning given such term
in section 447.502 of title 42, Code of Federal Regulations (or
any successor regulation).''.
SEC. 3. CALCULATION OF AVERAGE SALES PRICE UNDER MEDICARE.
Section 1847A(c)(3) of the Social Security Act (42 U.S.C. 1395w-
3a(c)(3)) is amended--
(1) by striking ``In calculating'' and inserting the
following:
``(A) In general.--Subject to subparagraph (B), in
calculating''; and
(2) by adding at the end the following new subparagraph:
``(B) Certain remuneration under value-based
purchasing arrangements excluded.--In calculating the
manufacturer's average sales price under this
subsection for a drug or biological that is sold under
a value-based purchasing arrangement (as defined in
section 1927(k)(12)) and with respect to which the
manufacturer of such drug or biological has elected to
include multiple best price points (as described in
section 1927(c)(1)(C)(ii)(VI)) in reporting the best
price of such drug under section 1927(b), such price
shall not include any amount that is excluded from the
calculation of the average manufacturer price of such
drug or biological under section
1927(k)(1)(B)(i)(IX).''.
SEC. 4. GUIDANCE ON VALUE-BASED PURCHASING ARRANGEMENTS FOR INPATIENT
DRUGS UNDER MEDICAID.
Not later than 180 days after the date of the enactment of this Act,
the Secretary of Health and Human Services shall issue guidance to
State Medicaid agencies on the option of entering into a value-based
purchasing arrangement (as defined in section 1927(k)(12) of the Social
Security Act (42 U.S.C. 1396r-8(k)(12))) with manufacturers for drugs
or biological products provided as part of, or as incident to and in
the same setting as, inpatient hospital services furnished under a
State plan under title XIX of the Social Security Act (42 U.S.C. 1396
et seq.), or under a waiver of such plan, where such drugs or
biological products are reimbursed directly and not paid for as part of
payment for such inpatient hospital services, including guidance on how
multiple States may enter into agreements with one another and with
manufacturers which permit the transfer of funds between the
participating States so that individuals who reside in a State
different from the State in which they receive a drug subject to a
value-based purchasing arrangement as an inpatient may be treated as if
they received such drug in the State in which they reside.
SEC. 5. EXCEPTION UNDER THE ANTIKICKBACK STATUTE.
(a) In General.--Section 1128B(b)(3) of the Social Security Act (42
U.S.C. 1320a-7b(b)(3)) is amended--
(1) in subparagraph (J), by moving the left margin of such
subparagraph 2 ems to the left;
(2) in subparagraph (K)--
(A) by moving the left margin of such subparagraph 2
ems to the left; and
(B) by striking ``and'' at the end;
(3) in subparagraph (L)(iii), by striking the period and
inserting ``; and''; and
(4) by adding at the end the following new subparagraph:
``(M) any remuneration provided by a manufacturer or
third party on behalf of a manufacturer to a State
under a value-based purchasing arrangement (as defined
in section 1927(k)(12)) under a State plan under title
XIX (or waiver of such plan) in the case a patient
fails to achieve outcomes or measures defined in such
arrangement following the administration of a covered
outpatient drug (as defined in section 1927(k)(2)).''.
(b) Rulemaking.--Not later than 180 days after the date of the
enactment of this Act, the Inspector General of the Department of
Health and Human Services shall through rulemaking implement the
amendments made by this section.
SEC. 6. GAO STUDY AND REPORT ON USE OF VALUE-BASED PURCHASING
ARRANGEMENTS.
(a) Study.--The Comptroller General of the United States shall
conduct a study on the extent to which value-based purchasing
arrangements (as defined in section 1927(k)(12) of the Social Security
Act (42 U.S.C. 1396r-8(k)(12)) facilitate patient access to covered
outpatient drugs, improve patient outcomes, lower overall health system
costs, and lower costs for patients in Federal health care programs. In
conducting such study, the Comptroller General shall--
(1) study the impact of this Act on--
(A) access to transformative therapies, including
rare disease gene therapies, generally;
(B) mitigating socioeconomic disparities in accessing
covered outpatient drugs sold under value-based
purchasing arrangements through its requirement that
State Medicaid programs have access to the same value-
based purchasing arrangement pricing structure that are
available in the commercial market for such drugs;
(C) the Medicaid drug rebate program under section
1927 of the Social Security Act (42 U.S.C. 1396r-8),
the 340B drug pricing program under section 340B of the
Public Health Service Act (42 U.S.C. 256b), and part B
of title XVIII of the Social Security Act (42 U.S.C.
1395j et seq.), including compliance with such
programs;
(D) expenditures under State Medicaid programs; and
(E) prices for such drugs under the Medicaid program
in States that do not enter into such arrangements;
(2) analyze all the types of value-based purchasing
arrangement pricing structures, which structures are working
well (as measured by price and ease of implementing), and which
need improvement; and
(3) study the potential long-term savings for States that
enter into such arrangements under State Medicaid programs.
(b) Report.--Not later than June 30, 2028, the Comptroller General of
the United States shall submit to Congress a report containing the
results of the study conducted under subsection (a).
Purpose and Summary
The bill amends Medicare and Medicaid policies to support
opportunities for States to enter into value-based purchasing
arrangements with drug manufacturers to manage the costs of
certain drugs in the Medicaid program.
Background and Need for Legislation
The current decade is poised to bring seismic changes to
health care, as breakthrough treatments for cell and gene
therapies come to market for the first time. Therapies to cure
diseases like sickle cell disease and hemophilia, diseases
where medicine could only help manage symptoms, could lead to
opportunities where patients no longer need regular doctors'
appointments and hospitalizations, saving them time and money
and supporting a more secure future.
The Medicaid program, which disproportionately covers
children and people with disabilities who stand to benefit the
most from many of these potential treatments, will be integral
in covering these therapeutics. However, many of these
treatments will likely be high-cost, one-time treatments that
will have significant budgetary implications for States in the
short run that could disrupt State financing and an ability to
cover these treatments, even if the eventual cures will save
States money in the long run.
As such, value-based purchasing arrangements have emerged
as a means for States to help manage these costs by allowing
States to pay over multiple installments for a drug and by
allowing States to pay for a drug only if the patient meets key
clinical endpoints. However, statutory barriers in Medicare and
Medicaid limit the ability for States to enter these types of
agreements. Thus, H.R. 2666 would make necessary amendments to
current law to facilitate these types of agreements.
Committee Action
On April 26, 2023, the Subcommittee on Health held a
hearing on H.R. 2666. The title of the hearing was ``Lowering
Unaffordable Costs: Legislative Solutions to Increase
Transparency and Competition in Health Care.'' The Subcommittee
received testimony from:
Chiquita Brooks-LaSure, Administrator, U.S.
Centers for Medicare and Medicaid Services;
Ashley Thompson, Senior Vice President,
Public Policy Analysis and Development, American
Hospital Association;
Kristin Bass, Chief Policy and External
Affairs Officer, Pharmaceutical Care Management
Association;
Brian Connell, Executive Director, Federal
Affairs, The Leukemia and Lymphoma Society;
Sean Cavanaugh, Chief Policy Officer,
Aledade, Inc.;
Ilyse Schuman, Senior Vice President, Health
Policy, American Benefits Council; and
Loren Adler, Fellow and Associate Director,
USC-Brookings Initiative for Health Policy, Economic
Studies Program, Brookings Institution.
On May 17, 2023, the Subcommittee on Health met in open
markup session and forwarded H.R. 2666, as amended, to the full
Committee by a record vote of 16 yeas and 11 nays.
On May 24, 2023, the full Committee on Energy and Commerce
met in open markup session and ordered H.R. 2666, as amended,
favorably reported to the House by a record vote of 31 yeas and
19 nays.
Committee Votes
Clause 3(b) of rule XIII requires the Committee to list the
record votes on the motion to report legislation and amendments
thereto. The following reflects the record votes taken during
the Committee consideration:
Oversight Findings and Recommendations
Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of
rule XIII, the Committee held a hearing and made findings that
are reflected in this report.
New Budget Authority, Entitlement Authority, and Tax Expenditures
Pursuant to clause 3(c)(2) of rule XIII, the Committee
finds that H.R. 2666 would result in no new or increased budget
authority, entitlement authority, or tax expenditures or
revenues.
Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to codify
value-based purchasing arrangements under the Medicaid program.
Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 2666 is known to be duplicative of another Federal
program, including any program that was included in a report to
Congress pursuant to section 21 of Public Law 111-139 or the
most recent Catalog of Federal Domestic Assistance.
Related Committee and Subcommittee Hearings
Pursuant to clause 3(c)(6) of rule XIII, the following
related hearing was used to develop or consider H.R. 2666:
On April 26, 2023, the Subcommittee on
Health held a hearing on H.R. 2666. The title of the
hearing was ``Lowering Unaffordable Costs: Legislative
Solutions to Increase Transparency and Competition in
Health Care.'' The Subcommittee received testimony
from:
Chiquita Brooks-LaSure,
Administrator, U.S. Centers for Medicare and
Medicaid Services;
Ashley Thompson, Senior Vice
President, Public Policy Analysis and
Development, American Hospital Association;
Kristin Bass, Chief Policy and
External Affairs Officer, Pharmaceutical Care
Management Association;
Brian Connell, Executive
Director, Federal Affairs, The Leukemia and
Lymphoma Society;
Sean Cavanaugh, Chief Policy
Officer, Aledade, Inc.;
Ilyse Schuman, Senior Vice
President, Health Policy, American Benefits
Council; and
Loren Adler, Fellow and
Associate Director, USC-Brookings Initiative
for Health Policy, Economic Studies Program,
Brookings Institution.
Committee Cost Estimate
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
Earmark, Limited Tax Benefits, and Limited Tariff Benefits
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 2666 contains no earmarks, limited
tax benefits, or limited tariff benefits.
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
Applicability to Legislative Branch
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
Section 1. Short title
Section 1 provides that the Act may be cited as the
``Medicaid VBPs for Patients Act'' or the ``MVP Act''.
Section 2. Codifying value-based purchasing arrangements under Medicaid
and reforms related to price reporting under such arrangements
Section 2 codifies the ability for drug manufacturers to
report multiple best prices in Medicaid for a drug, if the
manufacturer is engaged in a value-based purchasing arrangement
for the drug.
This section also amends the calculation of Average
Manufacturer Price to account for multiple best prices reported
for drugs in value-based purchasing arrangements, and requires
rulemaking to implement this provision.
The section also defines value-based purchasing
arrangements in statute.
Section 3. Calculation of average sales price under Medicare
Section 3 amends the calculation of Average Sales Price to
account for multiple best prices reported for drugs in value-
based purchasing arrangements.
Section 4. Guidance on value-based purchasing arrangements for
inpatient drugs under Medicaid
Section 4 requires the Department of Health and Human
Services (HHS) to issue guidance clarifying the ability for
States and manufacturers to enter into value-based purchasing
arrangements for drugs dispensed in inpatient settings.
Section 5. Exception under the Antikickback Statute
Section 5 creates an exception in the Antikickback Statute
for payments made by manufacturers to States when the
manufacturer is in a value-based purchasing agreement with a
State and when a patient in such an arrangement fails to
achieve outcomes or measures specified by the arrangement.
The section also requires rulemaking to implement this
section.
Section 6. GAO study and report on use of value-based purchasing
arrangements
Section 6 requires the Comptroller General to study the
extent to which value-based purchasing agreements facilitate
access to respective drugs.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (existing law
proposed to be omitted is enclosed in black brackets, new
matter is printed in italics, and existing law in which no
change is proposed is shown in roman):
SOCIAL SECURITY ACT
* * * * * * *
TITLE XI--GENERAL PROVISIONS, PEER REVIEW, AND ADMINISTRATIVE
SIMPLIFICATION
* * * * * * *
Part A--General Provisions
* * * * * * *
criminal penalties for acts involving federal health care programs
Sec. 1128B. (a) Whoever--
(1) knowingly and willfully makes or causes to be
made any false statement or representation of a
material fact in any application for any benefit or
payment under a Federal health care program (as defined
in subsection (f)),
(2) at any time knowingly and willfully makes or
causes to be made any false statement or representation
of a material fact for use in determining rights to
such benefit or payment,
(3) having knowledge of the occurrence of any event
affecting (A) his initial or continued right to any
such benefit or payment, or (B) the initial or
continued right to any such benefit or payment of any
other individual in whose behalf he has applied for or
is receiving such benefit or payment, conceals or fails
to disclose such event with an intent fraudulently to
secure such benefit or payment either in a greater
amount or quantity than is due or when no such benefit
or payment is authorized,
(4) having made application to receive any such
benefit or payment for the use and benefit of another
and having received it, knowingly and willfully
converts such benefit or payment or any part thereof to
a use other than for the use and benefit of such other
person,
(5) presents or causes to be presented a claim for a
physician's service for which payment may be made under
a Federal health care program and knows that the
individual who furnished the service was not licensed
as a physician, or
(6) for a fee knowingly and willfully counsels or
assists an individual to dispose of assets (including
by any transfer in trust) in order for the individual
to become eligible for medical assistance under a State
plan under title XIX, if disposing of the assets
results in the imposition of a period of ineligibility
for such assistance under section 1917(c),
shall (i) in the case of such a statement, representation,
concealment, failure, conversion, or provision of counsel or
assistance by any other person in connection with the
furnishing (by that person) of items or services for which
payment is or may be made under the program, be guilty of a
felony and upon conviction thereof fined not more than $100,000
or imprisoned for not more than 10 years or both, or (ii) in
the case of such a statement, representation, concealment,
failure, conversion, or provision of counsel or assistance by
any other person, be guilty of a misdemeanor and upon
conviction thereof fined not more than $20,000 or imprisoned
for not more than one year, or both. In addition, in any case
where an individual who is otherwise eligible for assistance
under a Federal health care program is convicted of an offense
under the preceding provisions of this subsection, the
administrator of such program may at its option
(notwithstanding any other provision of such program) limit,
restrict, or suspend the eligibility of that individual for
such period (not exceeding one year) as it deems appropriate;
but the imposition of a limitation, restriction, or suspension
with respect to the eligibility of any individual under this
sentence shall not affect the eligibility of any other person
for assistance under the plan, regardless of the relationship
between that individual and such other person.
(b)(1) Whoever knowingly and willfully solicits or receives
any remuneration (including any kickback, bribe, or rebate)
directly or indirectly, overtly or covertly, in cash or in
kind--
(A) in return for referring an individual to a person
for the furnishing or arranging for the furnishing of
any item or service for which payment may be made in
whole or in part under a Federal health care program,
or
(B) in return for purchasing, leasing, ordering, or
arranging for or recommending purchasing, leasing, or
ordering any good, facility, service, or item for which
payment may be made in whole or in part under a Federal
health care program,
shall be guilty of a felony and upon conviction thereof, shall
be fined not more than $100,000 or imprisoned for not more than
10 years, or both.
(2) Whoever knowingly and willfully offers or pays any
remuneration (including any kickback, bribe, or rebate)
directly or indirectly, overtly or covertly, in cash or in kind
to any person to induce such person--
(A) to refer an individual to a person for the
furnishing or arranging for the furnishing of any item
or service for which payment may be made in whole or in
part under a Federal health care program, or
(B) to purchase, lease, order, or arrange for or
recommend purchasing, leasing, or ordering any good,
facility, service, or item for which payment may be
made in whole or in part under a Federal health care
program,
shall be guilty of a felony and upon conviction thereof, shall
be fined not more than $100,000 or imprisoned for not more than
10 years, or both.
(3) Paragraphs (1) and (2) shall not apply to--
(A) a discount or other reduction in price obtained
by a provider of services or other entity under a
Federal health care program if the reduction in price
is properly disclosed and appropriately reflected in
the costs claimed or charges made by the provider or
entity under a Federal health care program;
(B) any amount paid by an employer to an employee
(who has a bona fide employment relationship with such
employer) for employment in the provision of covered
items or services;
(C) any amount paid by a vendor of goods or services
to a person authorized to act as a purchasing agent for
a group of individuals or entities who are furnishing
services reimbursed under a Federal health care program
if--
(i) the person has a written contract, with
each such individual or entity, which specifies
the amount to be paid the person, which amount
may be a fixed amount or a fixed percentage of
the value of the purchases made by each such
individual or entity under the contract, and
(ii) in the case of an entity that is a
provider of services (as defined in section
1861(u)), the person discloses (in such form
and manner as the Secretary requires) to the
entity and, upon request, to the Secretary the
amount received from each such vendor with
respect to purchases made by or on behalf of
the entity;
(D) a waiver of any coinsurance under part B of title
XVIII by a Federally qualified health care center with
respect to an individual who qualifies for subsidized
services under a provision of the Public Health Service
Act;
(E) any payment practice specified by the Secretary
in regulations promulgated pursuant to section 14(a) of
the Medicare and Medicaid Patient and Program
Protection Act of 1987 or in regulations under section
1860D-3(e)(6);
(F) any remuneration between an organization and an
individual or entity providing items or services, or a
combination thereof, pursuant to a written agreement
between the organization and the individual or entity
if the organization is an eligible organization under
section 1876 or if the written agreement, through a
risk-sharing arrangement, places the individual or
entity at substantial financial risk for the cost or
utilization of the items or services, or a combination
thereof, which the individual or entity is obligated to
provide;
(G) the waiver or reduction by pharmacies (including
pharmacies of the Indian Health Service, Indian tribes,
tribal organizations, and urban Indian organizations)
of any cost-sharing imposed under part D of title
XVIII, if the conditions described in clauses (i)
through (iii) of section 1128A(i)(6)(A) are met with
respect to the waiver or reduction (except that, in the
case of such a waiver or reduction on behalf of a
subsidy eligible individual (as defined in section
1860D-14(a)(3)), section 1128A(i)(6)(A) shall be
applied without regard to clauses (ii) and (iii) of
that section);
(H) any remuneration between a federally qualified
health center (or an entity controlled by such a health
center) and an MA organization pursuant to a written
agreement described in section 1853(a)(4);
(I) any remuneration between a health center entity
described under clause (i) or (ii) of section
1905(l)(2)(B) and any individual or entity providing
goods, items, services, donations, loans, or a
combination thereof, to such health center entity
pursuant to a contract, lease, grant, loan, or other
agreement, if such agreement contributes to the ability
of the health center entity to maintain or increase the
availability, or enhance the quality, of services
provided to a medically underserved population served
by the health center entity;
(J) a discount in the price of an applicable drug (as
defined in paragraph (2) of section 1860D-14A(g)) of a
manufacturer that is furnished to an applicable
beneficiary (as defined in paragraph (1) of such
section) under the Medicare coverage gap discount
program under section 1860D-14A;
(K) an incentive payment made to a Medicare fee-for-
service beneficiary by an ACO under an ACO Beneficiary
Incentive Program established under subsection (m) of
section 1899, if the payment is made in accordance with
the requirements of such subsection and meets such
other conditions as the Secretary may establish; [and]
(L) a bona fide mental health or behavioral health
improvement or maintenance program, if--
(i) such program--
(I) consists of counseling, mental
health services, a suicide prevention
program, or a substance use disorder
prevention and treatment program;
(II) is made available to a physician
or other clinician for the primary
purpose of preventing suicide,
improving mental health and resiliency,
or providing training in appropriate
strategies to promote the mental health
and resiliency of such physician or
other clinician;
(III) is set out in a written policy,
approved in advance of the operation of
the program by the governing body of
the entity providing such program (and
which shall be updated accordingly in
advance to substantial changes to the
operation of such program), that
includes--
(aa) a description of the
content and duration of the
program;
(bb) a description of the
evidence-based support for the
design of the program;
(cc) the estimated cost of
the program;
(dd) the personnel (including
the qualifications of such
personnel) implementing the
program; and
(ee) the method by which such
entity will evaluate the use
and success of the program;
(IV) is offered by an entity
described in clause (ii) with a formal
medical staff to all physicians and
other clinicians who practice in the
geographic area served by such entity,
including physicians who hold bona fide
appointments to the medical staff of
such entity or otherwise have clinical
privileges at such entity;
(V) is offered to all such physicians
Minority Views
H.R. 2666, the Medicaid VBPs for Patients Act, would not
expand access or increase affordability of drugs or gene
therapies in Medicaid. Instead, it would create a loophole in
federal law that would increase drug costs to Medicaid, further
straining state budgets and making it harder for states to care
for their most vulnerable populations.
Federal law generally requires state Medicaid programs to
cover all Food and Drug Administration (FDA)-approved drugs and
biologics of manufacturers that have a signed rebate agreement
in place. In exchange for this coverage requirement, drug
manufacturers are required to pay statutory rebates that are
shared between the states and the federal government.\1\ These
statutory rebates are a large source of revenue that help
states offset the costs of their Medicaid programs.\2\
---------------------------------------------------------------------------
\1\Medicaid and CHIP Payment and Access Commission (MACPAC),
Strengthening Evidence Under Medicaid Drug Coverage (March 2023).
\2\Id.
---------------------------------------------------------------------------
The Medicaid drug rebate program is highly effective at
reducing drug costs.\3\ Medicaid consistently has among the
lowest net drug costs of all federal health programs.\4\ A
drug's rebate is made up of a base rebate, which is the greater
of either 23.1 percent of the average manufacturer price (AMP)
for a brand drug, or the best price at which the drug is
available on the private market. Additionally, if the quarterly
AMP of the drug has increased over the base AMP of the drug at
a rate that exceeds inflation, manufacturers must pay an
inflationary rebate. Taken together, the Medicaid best price
and inflationary rebates are a substantial source of rebates in
Medicaid.
---------------------------------------------------------------------------
\3\Georgetown University Center for Children and Families, How to
Strengthen the Medicaid Drug Rebate Program to Address Rising Medicaid
Prescription Drug Costs (Jan. 2019).
\4\U.S. Government Accountability Office, Comparison of DOD,
Medicaid, and Medicare Part D Retail Reimbursement Prices (June 2014).
---------------------------------------------------------------------------
H.R. 2666 would create multiple loopholes in federal law
that would undermine both the Medicaid best price policy and
the inflationary rebates, resulting in decreased rebates and
increased drug costs to states and the federal government.
First, the bill would codify a regulation that allows drug
manufacturers to report multiple best prices for drugs in
value-based payment (VBP) arrangements. State Medicaid programs
would only be able to receive these discounts if they entered
into the same VBP that generated the best price. In other
words, if a drug's non-VBP best price results in a 25 percent
discount and the VBP best price results in a 50 percent
discount, a state would need to enter into that VBP arrangement
in order to receive the 50 percent discount.
Unfortunately, most, if not all states lack the financial
resources and administrative capabilities to participate in
VBPs, which means that under this structure, states will not
benefit from these VBP discounts. Accordingly, drug
manufacturers will be able to structure their most generous
discount agreements as VBPs with terms that make them
inaccessible to state Medicaid programs and, therefore, result
in reduced rebates and increased costs to Medicaid. This will
put further strain on state budgets.
In addition to the best price loophole, H.R. 2666 would
undermine Medicaid inflationary rebates by excluding VBP prices
from the calculation of AMP. A manufacturer launching a new
product would be able to structure some or all of its sales as
VBPs, which would artificially increase the AMP. By
artificially increasing the AMP, manufacturers will be able to
delay the onset of inflationary rebates. This will deprive
states and the federal government of yet another important
source of rebates and further strain state budgets.
Multiple commenters echoed these concerns and others in
their comments on the regulation that H.R. 2666 would codify.
The National Association of Medicaid Directors (NAMD), a
bipartisan association that represents all the state Medicaid
directors, said ``the rule's proposals would greatly favor
manufacturers over states in terms of financial benefit, have
significant impacts on the Medicaid pharmacy benefit, undermine
best price protections that ensure the sustainability of
Medicaid pharmacy budgets, and place substantial strain on
state administrative resources.''\5\ Similarly, the Medicaid
and CHIP Payment and Access Commission (MACPAC) wrote ``[t]he
proposed definition of VBP and changes to Medicaid best price
could lead to decreased rebates, and thus increased Medicaid
spending, while also increasing administrative burden on
states. Specifically, the Commission is concerned that while
these changes could incentivize the use of VBP in the
commercial market, they would also negatively affect the
Medicaid program and do little to address concerns about the
impact of high-cost specialty drugs on Medicaid program
spending.''\6\
---------------------------------------------------------------------------
\5\National Association of Medicaid Directors, Comments on Medicaid
Program; Establishing Minimum Standards in Medicaid State Drug
Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP)
for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third
Party Liability (TPL) Requirements'' [CMS-2482-P] (July 20, 2020).
\6\MACPAC, Comments on Medicaid Program; Establishing Minimum
Standards in Medicaid State Drug Utilization Review (DUR) and
Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid,
Revising Medicaid Drug Rebate and Third Party Liability (TPL)
Requirements (July 20, 2020).
---------------------------------------------------------------------------
H.R. 2666 would codify harmful changes to the Medicaid drug
rebate program that would increase costs to states and the
federal government. It would create multiple loopholes,
increase administrative burdens on states, and fail to increase
access or reduce the cost of drugs to state Medicaid programs.
Frank Pallone, Jr.,
Ranking Member.
[all]